Navigation Links
J. Craig Venter, Ph.D. to Receive National Medal of Science From President Obama

ROCKVILLE, Md., Sept. 18 /PRNewswire-USNewswire/ -- J. Craig Venter, Ph.D., founder, president and chairman of the J. Craig Venter Institute (JCVI), has been named a recipient of this year's National Medal of Science. Dr. Venter will be awarded the Medal from President Obama on October 7 at a White House ceremony.

The National Medal of Science, the highest honor awarded to scientists by the United States government, was created by statute in 1959 and is administered for the White House by the National Science Foundation. Awarded annually, the Medal recognizes individuals who have made outstanding contributions to science and engineering. Nominees are selected by a committee of Presidential appointees based on their advanced knowledge in, and contributions to, the biological, behavioral/social, and physical sciences, as well as chemistry, engineering, computing, and mathematics.

According to the official citation, Dr. Venter is being recognized for his dedication to the advancement of the science of genomics, his contributions to the understanding of its implications for society, and his commitment to the clear communication of information to the scientific community, the public, and policymakers.

Dr. Venter and his teams have been continuous pioneers in the field of genomics. Beginning in the late 1980's they were the first to successfully use new automated DNA sequencers to sequence human genes. They then used these same technologies to develop and publish in 1991 Expressed Sequence Tags (ESTs), Dr. Venter's new method to rapidly discover human genes. Since then more than 65 million EST's have been generated by the scientific community from a broad range of species.

In 1995 he and his team sequenced the first full genome of a free living organism, the bacteria Haemophilus influenzae, by a new method they developed called "whole genome shotgun sequencing". This first genome led to the rapid and accurate decoding of hundreds of important genomes including human viral and bacterial pathogens, environmental microbes, insect, plant and mammalian genomes. More than 95% of genomes sequenced have been done using Dr Venter's methods. Only five years after developing this new method, Dr Venter's team announced the first draft human genome in 2000. They continued their work on sequencing and analyzing the human genome and published the first complete diploid genome in 2007.

Dr. Venter has since applied these same DNA sequencing approaches to catalogue the genomes of the microbes living in a variety of environments. The Venter Institute's Sorcerer II Expedition has discovered more than 20 million new genes from microbes in the world's oceans. Other environments including the human gut, mouth and skin are yielding similarly important new insights into the microbes inhabiting the human body. These research projects helped to begin the new fields known as environmental genomics and metagenomics.

Dr. Venter and colleagues also pioneered the new field of synthetic genomics and are trying to create the first world's first synthetic cell.

In addition to his work and leadership at the Venter Institute, Dr. Venter is also founder and CEO of Synthetic Genomics Inc, a privately held company applying genomic-driven solutions to address a variety for global challenges starting first with energy and the environment. Dr. Venter is the author of more than 250 major research articles and is among the most cited scientists in the world. He is also the recipient of numerous honorary degrees, scientific awards and a member of many prestigious scientific organizations including the National Academy of Sciences.

About the J. Craig Venter Institute

The JCVI is a not-for-profit research institute in Rockville, MD and San Diego, CA dedicated to the advancement of the science of genomics; the understanding of its implications for society; and communication of those results to the scientific community, the public, and policymakers. Founded by J. Craig Venter, Ph.D., the JCVI is home to approximately 400 scientists and staff with expertise in human and evolutionary biology, genetics, bioinformatics/informatics, information technology, high-throughput DNA sequencing, genomic and environmental policy research, and public education in science and science policy. The legacy organizations of the JCVI are: The Institute for Genomic Research (TIGR), The Center for the Advancement of Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA), the Joint Technology Center (JTC), and the J. Craig Venter Science Foundation. The JCVI is a 501 (c) (3) organization. For additional information, please visit

SOURCE J. Craig Venter Institute
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Craig Johnson Joins Ardea Biosciences Board of Directors
2. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
3. J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology
4. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
5. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
8. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs
11. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):